Table 2 Logistic regression analysis on determinants of maximal RAASi vs. submaximal RAASi
Univariate | Multivariate | |
|---|---|---|
Exp(B) (95% CI) | ||
Age years | 1.00 (0.98–1.03) | … |
Gender, women vs. men | 0.72 (0.49–1.04) | … |
Body mass index, kg/m2 | 1.01 (0.98–1.05) | … |
SBP, mmHg | 1.01 (0.99–1.02) | … |
DBP, mmHg | 1.00 (0.99–1.02) | … |
Heart frequency, beats/min | 0.99 (0.98–1.01) | … |
Smokers vs. non-smokers | 0.93 (0.55–1.58) | … |
Years since type 2 diabetes diagnosis, years | 1.02 (1.00-1.04) | … |
Serum HbA1c, mmol/mol | 0.99 (0.98–1.01) | … |
Insulin use | 0.89 (0.60–1.31) | … |
eGFR < 60 ml/min/1.73m2 | 0.79 (0.53–1.19) | … |
Albuminuria | 1.67 (1.14–2.45) | 1.89 (1.17–3.08) |
Retinopathy | 1.14 (0.75–1.74) | … |
Polyneuropathy | 0.90 (0.62–1.31) | … |
Coronary heart disease | 0.97 (0.63–1.49) | … |
Cerebrovascular disease | 0.71 (0.41–1.22) | 0.43 (0.21–0.90) |
Total number of antihypertensives | 1.49 (1.26–1.77) | 1.66 (1.33–2.06) |
Prebaseline hyperkalemia > 6 mmol/L | 0.99 (0.34–2.91) | … |
Number of prebaseline hyperkalemia events | ||
0 | ref | … |
1–2 times | 0.96 (0.43–2.18) | … |
3–5 times | 0.91 (0.35–2.33) | … |
> 5 times | 1.04 (0.32–3.40) | … |
Number of prebaseline acute kidney injury events | 0.60 (0.40–0.89) | 0.51 (0.30–0.87) |